Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder Cancer

Funder: National Cancer Institute

Funding period
USD 1.1 M
Funding amount
Project Summary/Abstract It has known that bladder cancer (BCa) mortality is higher in African American patients. Disparity exists between African-American (AA) and European-American (EA), in the clinical outcome of BCa. The long-term objective of our research plan is to reduce the disproportionate effects of bladder cancer (BCa) on African American. A guiding principle of our methodology is that alterations in mitochondrial metabolites exist between African American and European American BCa and that these differences can explain, in part, BCa health disparity. In this application, we propose to use the technique of metabolomic profiling to uncover these underlying differences. To date, a metabolomic analyses aimed at understanding of bladder cancer health disparity has not been reported. We have recently published the first study describing metabolic alterations associated with bladder cancer. In preliminary studies, we have profiled the metabolome of BCa from AA and EA patients and identified a distinct AA race-specific expression pattern in mitochondrial metabolites and lipids. In this proposal, we will i) characterize the mitochondrial associated metabolites in AA and EA BCa, ii) verify the D-2HG and associated enzymes (GLS, ADHFE1, and IDH1/2) in BCa patients and establish a therapeutically targeted deregulation pathway for glutamine metabolism in AA BCa iii) assess the levels of lyso PC and PC and the function of their metabolizing enzymes PLA1A and LRAT in AA BCa. The successful completion of the proposed studies will have a significant impact in the field of Bladder cancer health disparity and metabolism. Importantly, findings from our study have the potential to reveal racially exclusive metabolic markers and therapeutic targets for BCa. Taken together, the information gleaned from this proposal could rapidly revolutionize current diagnostic, prognostic and therapeutic approaches by revealing the biological underpinnings of bladder cancer health disparity.
Similar projects All >
Sorted by: Start Date
Project list item
DNA adductome of human bladder from the tobacco exposome

National Institute of Environmental Health Sciences to ROBERT J. TURESKY

USD 922,448
2019 - 2023
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2020
Project list item
Targeting TAM (Tyro3-Axl-Mer) family of transmembrane receptor tyrosine kinases in bladder cancer.

Bladder Cancer Advocacy Network to Arpita Roy

USD 1,700
2018 - 2018
Project list item
Novel Biomarkers for the Clinical Management of Bladder Cancer

National Cancer Institute to VINATA B LOKESHWAR

USD 902,622
2018 - 2023



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC

    Urologic Diseases




    2.1 Biological and endogenous factors

  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science